The City of Huntsville has taken another step toward bringing pharmaceutical giant Eli Lilly’s $6 billion facility to the ...
Eli Lilly and Company has delivered significant positive developments this week, though its shares experienced a minor pullback in Wednesday's trading sessio ...
It doesn't have the highest yield, but it has enviable dividend coverage and a long history of surviving in a competitive ...
The Chosun Ilbo on MSN
Oral obesity drugs near FDA approval, domestic launch planned
New obesity treatments such as 'oral Mounjaro' and 'high-dose Wegovy' are scheduled to be released next year. The U.S. Food ...
Explore Pfizer Inc.’s 2025-2026 outlook: challenges, flat revenues, patent risks, and potential from the Metsera deal. Click ...
Though it hasn't even wrapped up clinical trials, the weight loss drug retatrutide already has a cult following.
Eli Lilly’s retatrutide exceeds expectations in Phase III, capping off a sparkling 2025 for the obesity titan; an internal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback